To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Intestinal Microbiota in … - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Intestinal Microbiota in Cardiovascular Health and Disease

Journal article
Authors W. H. W. Tang
Fredrik Bäckhed
U. Landmesser
S. L. Hazen
Published in Journal of the American College of Cardiology
Volume 73
Issue 16
Pages 2089-2105
ISSN 0735-1097
Publication year 2019
Published at Institute of Medicine, Department of Molecular and Clinical Medicine
Pages 2089-2105
Language en
Keywords dysbiosis, intestinal microbiota, secondary bile acids, short-chain fatty acid, trimethylamine N-oxide, trimethylamine-n-oxide, coronary-artery-disease, gut microbiota, heart-failure, l-carnitine, blood-pressure, myocardial-infarction, wide, association, fish consumption, prognostic value, Cardiovascular System & Cardiology
Subject categories Cardiac and Cardiovascular Systems


Despite major strides in reducing cardiovascular disease (CVD) burden with modification of classic CVD risk factors, significant residual risks remain. Recent discoveries that linked intestinal microbiota and CVD have broadened our understanding of how dietary nutrients may affect cardiovascular health and disease. Although next-generation sequencing techniques can identify gut microbial community participants and provide insights into microbial composition shifts in response to physiological responses and dietary exposures, provisions of prebiotics or probiotics have yet to show therapeutic benefit for CVD. Our evolving understanding of intestinal microbiota-derived physiological modulators (e.g., short-chain fatty acids) and pathogenic mediators (e.g., trimethylamine N-oxide) of host disease susceptibility have created novel potential therapeutic opportunities for improved cardiovascular health. This review discusses the roles of human intestinal microbiota in normal physiology, their associations with CVD susceptibilities, and the potential of modulating intestinal microbiota composition and metabolism as a novel therapeutic target for CVD. (C) 2019 by the American College of Cardiology Foundation.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?